New Data Highlights VYVGART's Efficacy and Safety in Myasthenia Gravis Patients Across All Subtypes.
ByAinvest
Wednesday, Oct 29, 2025 11:02 am ET1min read
ARGX--
argenx presents new data at AANEM and MGFA highlighting VYVGART's efficacy across gMG subtypes. ADAPT SERON results show VYVGART achieved minimal symptom expression in ~60% of patients, with 88% sustaining this for at least 4 weeks. Real-world data show >70% of patients treated with VYVGART meaningfully reduced glucocorticoid use while maintaining clinical benefit.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet